Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.47 (market cap $28.50B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF and Royalty Pharma plc Class A Ordinary Shares are close in size by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| LQD | RPRX | |
|---|---|---|
Market Cap | $28.50B | $25.27B |
Volume | 37,320,110 | 3,671,183 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $63.96 |
52-Week Low | $101.83 | $35.44 |
Typical Hold Time | 125 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.41 with a slight 0.28% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs. The fund maintains consistent dividend distributions with recent payouts around $0.44-0.46 per share.
The outlook remains cautious given the bearish technical setup and rising bond yields pressuring corporate debt valuations. Key risks include continued bond market volatility and higher borrowing costs for issuers. Investment opportunities exist for income-focused investors seeking exposure to investment-grade corporate bonds, though near-term price pressure may persist until bond market conditions stabilize.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
